AnaptysBio (NASDAQ:ANAB) Trading Down 5.9%

AnaptysBio, Inc. (NASDAQ:ANAB) shares traded down 5.9% during mid-day trading on Thursday . The stock traded as low as $20.10 and last traded at $20.20. 214,966 shares changed hands during trading, a decline of 31% from the average session volume of 311,290 shares. The stock had previously closed at $21.47.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Stifel Nicolaus assumed coverage on shares of AnaptysBio in a research note on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective for the company. Wedbush upgraded shares of AnaptysBio from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $20.00 to $34.00 in a research note on Tuesday, March 12th. BTIG Research began coverage on shares of AnaptysBio in a research note on Monday, February 26th. They set a “buy” rating and a $55.00 price objective for the company. SVB Leerink initiated coverage on shares of AnaptysBio in a research report on Tuesday. They set an “outperform” rating and a $47.00 target price on the stock. Finally, Leerink Partnrs reissued an “outperform” rating on shares of AnaptysBio in a report on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.22.

AnaptysBio Trading Down 7.6 %

The stock’s 50-day moving average is $23.38 and its 200-day moving average is $20.55. The stock has a market cap of $530.65 million, a P/E ratio of -3.26 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.74) by $0.15. The company had revenue of $9.01 million during the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. On average, equities analysts forecast that AnaptysBio, Inc. will post -6.25 EPS for the current year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 145,940 shares of the firm’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the transaction, the chief executive officer now directly owns 752,087 shares in the company, valued at $17,132,541.86. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Daniel Faga sold 145,940 shares of the firm’s stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the sale, the chief executive officer now directly owns 752,087 shares in the company, valued at $17,132,541.86. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Dennis Mulroy sold 3,065 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $23.63, for a total transaction of $72,425.95. Following the transaction, the chief financial officer now directly owns 964 shares in the company, valued at approximately $22,779.32. The disclosure for this sale can be found here. Insiders have sold 157,005 shares of company stock valued at $3,586,199 in the last quarter. Insiders own 35.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in AnaptysBio by 2.1% during the first quarter. BlackRock Inc. now owns 1,895,494 shares of the biotechnology company’s stock valued at $41,246,000 after acquiring an additional 39,228 shares in the last quarter. Vanguard Group Inc. raised its position in AnaptysBio by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,745,108 shares of the biotechnology company’s stock valued at $44,518,000 after acquiring an additional 14,638 shares in the last quarter. State Street Corp raised its position in AnaptysBio by 10.0% during the third quarter. State Street Corp now owns 1,271,727 shares of the biotechnology company’s stock valued at $32,442,000 after acquiring an additional 115,846 shares in the last quarter. First Light Asset Management LLC raised its position in AnaptysBio by 56.4% during the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after acquiring an additional 446,372 shares in the last quarter. Finally, Woodline Partners LP raised its position in AnaptysBio by 125.1% during the second quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock valued at $21,043,000 after acquiring an additional 574,987 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.